Cell transformation by v-Jun deactivates ERK MAP kinase signalling

Elizabeth J Black1, Mark Walker, William Clark

  • 1Beatson Institute for Cancer Research, Cancer Research UK Beatson Laboratories, Garscube Estate, Switchback Road, Bearsden, Glasgow G61 1BD, UK.

Oncogene
|September 13, 2002
PubMed

Insights

v-Jun transformation disrupts cell cycle control by inhibiting the ERK pathway. This involves reduced ERK activity and impaired signaling, impacting cell growth and potentially contributing to oncogenesis.

Area of Science:

  • Cell Biology
  • Molecular Biology
  • Oncogenesis

Background:

  • v-Jun accelerates G1 progression and S phase entry without growth factors.
  • Growth factor-dependent ERK MAP kinase signaling regulates the G1/S transition.

Purpose of the Study:

  • Investigate if aberrant ERK regulation contributes to v-Jun-induced cell cycle deregulation.
  • Determine the effects of v-Jun transformation on ERK signaling pathways.

Main Methods:

  • Biochemical analysis of ERK pathway components.
  • Assessing ERK activity and responsiveness to various agonists in v-Jun transformed cells.

Main Results:

  • v-Jun transformed cells show reduced basal and stimulated ERK activity.
  • ERK signaling becomes refractory to serum, LPA, and EGF but partially responsive to TPA.
  • Defects linked to inefficient Ras-Raf signal propagation and increased MAP kinase phosphatase activity.

Conclusions:

  • v-Jun transformation antagonizes ERK signaling at multiple levels.
  • Altered cell physiology in v-Jun transformed cells impacts ERK signaling.
  • This phenotype may have significance in v-Jun-mediated oncogenesis.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...